Leqselvi launch delay due to litigation
Incyte filed a preliminary injunction motion to block Leqselvi launch; outcome uncertain and could delay revenue contribution.
high · management_commentary
Sunpharma Ltd — Q1 FY25
Sun Pharma reported a solid Q1 FY25 with consolidated sales of INR 12,524.5 crore (+6.3% YoY) and EBITDA margin expansion of 60 bps to 28.5%.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Halol plant re-audit timeline uncertain
Management plans to request FDA re-audit once ready, but no specific timeline provided; pending approvals may impact U.S. generic pipeline.
medium · analyst_questionU.S. generic revenue flat despite Revlimid contribution
U.S. generic sales were flat sequentially; Revlimid contribution was not large this quarter, and sustainability is uncertain.
medium · data_observation